3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gastrointestinal
1
Conditions
Tumor Lysis Syndrome
1
Tongue Neoplasms
1
Thyroid cancer, Hurthle cell
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Thromboembolism
1
Teratogenesis
1
Squamous Cell Carcinoma of Head and Neck
1
Sleepiness
1
Seizures
1
Salivary Gland Neoplasms
1
Renal Insufficiency
1
Rectal Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Peripheral Nervous System Diseases
1
Neoplasms, Second Primary
1
Lymphoma
1
Lymphoid Interstitial Pneumonia
1
Lung Diseases, Interstitial
1
Infections
1
Hypothyroidism
1
Hypotension, Orthostatic
1
Hypersensitivity
1
Hemorrhage
1
Heart Failure
1
Head and Neck Neoplasms
1
Fatigue
1
Dizziness
1
Digestive System Diseases
1
Coronary Artery Disease
1
Interventions
Cisplatin
280
pembrolizumab
234
Radiotherapy
171
Cetuximab
168
Carboplatin
123
Docetaxel
109
Paclitaxel
96
Fluorouracil
95
Nivolumab
88
Radiotherapy, Intensity-Modulated
80
Magnetic Resonance Spectroscopy
39
durvalumab
36
Radiation
33
Surgical Procedures, Operative
32
Drug Therapy
32
Biopsy
28
Radiosurgery
25
Erlotinib Hydrochloride
25
Albumin-Bound Paclitaxel
24
Taxes
23
130-nm albumin-bound paclitaxel
23
Specimen Handling
22
Platinum
22
Immunohistochemistry
21
tislelizumab
20
1,2-diaminocyclohexaneplatinum II citrate
20
Chemoradiotherapy
19
Capecitabine
19
tremelimumab
18
Neoadjuvant Therapy
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Squamous Cell Carcinoma of Head and Neck
×
Lenalidomide
×
Head & Neck
×
Clear all
NCT01254617
2020-03-13
ADCC
National Cancer Institute (NCI)
Phase 1
Completed
24 enrolled